Chinanews.com, April 21. "The drug regulatory department requires that special attention be paid to the thrombosis problem of the adenovirus vector vaccine in the monitoring. China has a very sound adverse reaction monitoring system, which can reassure the people that once any problems are found, they will Take measures." Shao Yiming, a member of the expert group of the vaccine research and development team of the scientific research team, made the above statement when answering questions from reporters on the 21st.
On the 21st, the State Council’s Joint Prevention and Control Mechanism held a press conference on the new crown vaccination situation.
The reporter asked at the meeting that the New England Journal of Medicine published an article not long ago discussing the adverse reaction of thrombosis after AstraZeneca vaccination.
In addition, some media reported that Johnson & Johnson vaccine was associated with several cases of thrombosis.
Johnson & Johnson vaccines and AstraZeneca vaccines both use adenovirus vectors. How should we view the relationship between adenovirus vector vaccines and thrombosis?
Has China's adenovirus vector vaccine research and development paid attention to this issue and what work has been done?
Shao Yiming said that safety is the primary consideration for vaccines.
The New England Journal published an article, which also attracted great attention from the drug regulatory system of various countries.
The European Union's drug regulatory authorities have conducted serious studies. They have confirmed through several meetings that thrombosis is indeed related to vaccination.
In addition, the US drug regulatory system and CDC have also made a decision to suspend Johnson & Johnson's use of adenovirus vector vaccines. They have also observed a similar situation and are preparing to meet to decide what to do with Johnson & Johnson's vaccine.
Shao Yiming emphasized two points: First, it is an extremely rare event, with an occurrence rate of about 200,000 to one in a million. In this sense, it is an extremely rare event.
The second is that it occurs in people of different age groups. Therefore, considering the benefit-risk ratio of the vaccine, the older the person, the higher the risk of infection, and the greater the benefit-risk ratio of vaccination. Therefore, countries have also noticed that Europe The drug regulatory authorities of some countries have decided not to use it for people under the age of 50, 55, and 60. The United Kingdom has decided not to use it for people under 30.
Shao Yiming said that in this case, the Chinese government also pays great attention to the fact that China Cansino’s vaccine is currently inoculated to almost one million people, and similar reports have not been observed.
However, the drug regulatory department requires that special attention be paid to the problem of thrombosis in the use of adenovirus vector vaccines during monitoring.
China has a very sound adverse reaction monitoring system, which can reassure the people that if any problems are found, measures will be taken.
Shao Yiming pointed out that, in a general sense, the risk-benefit ratio of vaccines is far greater than the rare incidence of adverse events. In many countries and regions, especially in developing countries, there is a serious shortage of vaccines. All kinds of vaccines can be promoted and used as long as they follow scientific data and effective monitoring.